LIFE- undersøgelsen LIFE (The Losartan Intervention For Endpoint Reduction In Hypertension) var en randomiseret, trippelblindet, aktiv kontrolleret undersøgelse foretaget hos 9193 hypertensive patienter i alderen 55- 80 år med EKG- diagnosticeret hypertrofi af venstre ventrikel.
LIFE Study The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was a randomised, triple-blind, active-controlled study in 9193 hypertensive patients aged 55 to 80 years with ECG- documented left ventricular hypertrophy.